Access physician-administered drug pricing and coding information at the HCPCS Unit Level.
Access Self-Administered drug pricing and coding information at the NDC Level.
Monitor all of their product listings on key pricing and coding databases used by payers, pharmacies and providers.
Disease-specific and category-based analytical reports.
From: BuyandBill.com <info@buyandbill.com>
To: [customer]
Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)
Effective January 1, 2023:
J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from
The Centers for Medicare and Medicaid (CMS)1
HCPCS
Code
HCPCS Code
Descriptor
NDC
Number
How
Supplied
APC Per HCPCS Unit (1 mg)
HCPCS Units Per Package
J1932
injection, lanreotide, (Cipla), 1 mg
69097-0870-67
Lanreotide Acetate Subcutaneous Solution 120/MG/.05mL
$60.378
120
Please contact us @ Account.Management@Cipla.com
© Copyright 2023 Cipla USA Inc. All rights reserved
January 2023 CUSAI-09292022-01
References: 1. https://www.cms.gov/license/ama?file=/files/zip/january-2023-opps-addendum-b.zip